ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Hatch To Speak At AACI Dinner; NIH Plans 1987 Centennial; Cox To Head Columbia Radiotherapy

May 24, 1985

ASCO Says FDA Plan For ESA Management Will Burden Oncologists

March 5, 2010

NCI to Fund Research Collaboration At HMOs, Health Care Provider Networks

July 11, 1997

NCI Cooperative Group, Cancer Center Trials Listed

December 26, 2008

Blackburn Wins BMS Award

May 23, 2003

In Brief: Travel Grants available For 14th International Congress; NIH Seeks Nurses For Study Sections

November 22, 1985